Patent ID: 7947653

Claim:
A method of treating an Epidermal Growth Factor Receptor tyrosine kinase inhibitor-resistant cancer in a subject with a combination drug therapy, the method comprising: administering to a subject with an Epidermal Growth Factor Receptor tyrosine kinase inhibitor-resistant cancer a combination comprising an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor, wherein: (a) the Epidermal Growth Factor Receptor tyrosine kinase inhibitor is erlotinib or gefitinib; (b) the Interleukin-6 inhibitor is an anti-Interleukin-6 antibody or an anti-Interleukin-6 receptor antibody; (c) the Epidermal Growth Factor Receptor tyrosine kinase inhibitor and the Interleukin-6 inhibitor are each administered in an amount that is therapeutically effective when the two are administered as a combination drug therapy; and (d) wherein the Epidermal Growth Factor Receptor tyrosine kinase inhibitor-resistant cancer is a Non Small Cell Lung Carcinoma, breast cancer, or pancreatic cancer.